Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 2Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Mastocytosis, Systemic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Hairy Cell 1Kidney Neoplasms 1Hodgkin Disease 1Hematologic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Medullary 1Burkitt Lymphoma 1Breast Carcinoma In Situ 1Brain Neoplasms 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1Advanced Cancer 1

Interventions

aldesleukin 26Sunitinib 25Interferon-alpha 21Everolimus 18Sorafenib 16Cyclophosphamide 16Filgrastim 13Bevacizumab 13Nivolumab 11Gemcitabine 11Interleukin-2 10Axitinib 10fludarabine phosphate 9Gene Expression Profiling 9temsirolimus 8Peripheral Blood Stem Cell Transplantation 8Doxorubicin 8pembrolizumab 7Radiotherapy 6Radiosurgery 6Polymerase Chain Reaction 6Ipilimumab 6Carboplatin 6sargramostim 5Ifosfamide 5Fluorouracil 5Erlotinib Hydrochloride 5Capecitabine 5Bortezomib 5atezolizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Kidney Neoplasms × Ranitidine × Clear all
NCT00030992 2012-08-20

BMS 247550 to Treat Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
102 enrolled 10 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡